ARKA Clinical Decision Support is designed to meet all four criteria for Non-Device CDS under FD&C Act §520(o)(1)(E) and FDA's January 2026 final guidance on Clinical Decision Support Software. Recommendations support, not replace, the clinician's judgment. Every recommendation is anchored in a published guideline or peer-reviewed source, with the basis available for independent review. CLIN emphasizes imaging appropriateness at order entry.
This recommendation is intended to support, not replace, clinical judgment. It is generated by ARKA, software designed to meet the four criteria for Non-Device Clinical Decision Support under FD&C Act §520(o)(1)(E) and FDA's final guidance on Clinical Decision Support Software (January 2026). The clinician is responsible for the final decision.
AIIE Evidence
Begin screening mammography at 40 for average-risk women; tomosynthesis is the preferred technique where offered.
Screening mammography for average-risk women is recommended beginning at age 40 (USPSTF 2024: biennial 40–74). Digital breast tomosynthesis improves recall rates and cancer detection where available.
The AIIE synthesis above is ARKA-authored; the sources below are the underlying external literature.
U.S. Preventive Services Task Force · 2024
American College of Radiology · 2024